Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

Study Overview

• Status: Active, not recruiting
• Conditions: Atopic Dermatitis; Atopic Dermatitis Eczema; Atopic Dermatitis of Scalp
• Intervention / Treatment: Other: Placebo; Drug: HY209GEL Active

Detailed Description

Part 1 (2 cohorts): Total 33 subjects

• Cohort A: 15 subjects (6 HY209gel 0.5%, 6 HY209gel 1%, and 3 placebo)
• Cohort B: 9 subjects (6 HY209gel 2%, and 3 placebo)
• Cohort C: 9 subjects (6 HY209gel 4%, and 3 placebo)

Part 2 (3 treatment groups): Total 177 subjects

• Low dose of HY209gel: 59 subjects
• High dose of HY209gel: 59 subjects
• Placebo (Vehicle): 59 subjects

Part 1 is a dose-escalation part of HY209gel using lower doses of HY209gel (0.5% and 1%) with escalation (HY209gel 2% and 4%) to evaluate the pharmacokinetics(PK), safety, and tolerability of HY209gel treatment. Escalation to the next dose level will be decided by the Safety Monitoring Committee(SMC) that will review all available safety data of the planned dose level within the timeline specified on SMC charter after all enrolled subjects of each cohort complete 2-week treatment and determine the escalation to the next dose to be safe.

Based on the interim analysis for 4-week safety and efficacy data collected from Part 1, two doses will be selected for use in Part 2, which will enroll up to 177 subjects in 3 treatment arms (59 subjects per treatment arm) to evaluate the efficacy and safety of HY209gel, compared to placebo (vehicle) for 8-week treatment period.

• Study Type: Interventional
• Enrollment (Estimated): 210
• Phase: Phase 2

Contacts and Locations

Study Locations

• South Korea
  • Seoul, South Korea
    • Seoul National University Hospital
  • Seoul, South Korea
    • Severance Hospital, Yonsei University Health System
  • Seoul, South Korea
    • Seoul National University Bundang Hospital
  • Seoul, South Korea
    • Gachon University Gil Medical Center
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35244
      • Cahaba Dermatology Skin Health Center
  • California
    • Encino, California, United States, 16133
      • RAOOF MD Dermatology
    • Los Angeles, California, United States, 90057
      • L.A. Universal Research Center, Inc.
    • Los Angeles, California, United States, 90212
      • Zenith Research Inc.
  • Maryland
    • Towson, Maryland, United States, 21204
      • Continental Clinical Solutions, LLC
  • Michigan
    • Southfield, Michigan, United States, 19505
      • Revival Research Institute, LLC
  • New York
    • New York, New York, United States, 10075
      • Sadick Dermatology
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • University of Pittsburgh Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Male or female subjects aged 18 or older
• Subjects who have a history of AD at least 6 months ago from screening and have been clinically stable for ≥ 1 month
• Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist
• Subjects who have a minimum of 5% and a maximum of 30% of total body surface area (BSA) affected by AD at screening and baseline visits
• Subjects with vIGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visit
• Subjects should be a literate person who can read the participant information sheet and consent form/questionnaire and understand the language of the participation

Key Exclusion Criteria:

• Subjects who have unstable AD (i.e., remaining clinical stable less than 6 months) or any consistent requirement for any potency topical corticosteroids
• Subjects who have topical treatment with corticosteroids within 2 weeks prior to baseline visit or other topical treatments of the AD area at screening (moisturizers/emollients are allowed)
• Subjects who had systemic treatment with corticosteroids or cyclosporine or other immunosuppressive treatments within 4 weeks prior to baseline visit
• Subjects who had dupilumab or any other biologics within 6 months prior to baseline visit
• Subjects who take any systemic anti-infective or antibiotic treatments within 1 week prior to baseline visit
• Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks prior to screening
• Subjects who have active malignancy or history of cancer in 5 years prior to screening, except for treated cautions basal cell carcinoma and in situ cervical cancer
• Subjects who have any other skin diseases that would affect the ability to assess the AD
• Subjects who are taking any other concomitant drug that, in the opinion of the PI, may cause interference with the treatment
• Subjects who participated in another drug or device trial within 4 weeks prior to screening...etc

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: PART 2 High-Dose; Active group selected for PART1 as a high-dose	Drug: HY209GEL Active; Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
Active Comparator: PART 2 Low-Dose; Active group selected for PART1 as a Low-dose	Drug: HY209GEL Active; Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
Placebo Comparator: PART 2 Placebo; Placebo group	Other: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage change in Eczema Area and Severity Index (EASI) score	To achieve lower score means disease improvement .	at Week 8

Collaborators and Investigators

• Sponsor: Shaperon

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2024
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): August 31, 2026

Study Registration Dates

• First Submitted: July 24, 2023
• First Submitted That Met QC Criteria: August 31, 2023
• First Posted (Actual): September 6, 2023

Study Record Updates

• Last Update Posted (Actual): February 23, 2026
• Last Update Submitted That Met QC Criteria: February 19, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Immune System Diseases; Hypersensitivity, Immediate; Hypersensitivity; Skin Diseases; Skin Diseases, Genetic; Skin Diseases, Eczematous; Dermatitis; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Dermatitis, Atopic
• Other Study ID Numbers: HY209-AD-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No